CONCORD HC GP (02453) announced that it expects revenue for the first half of 2026 to be approximately 260 million to 280 million yuan, compared to about 200.9 million yuan recorded in the six months ended June 30, 2025, representing a year-on-year increase of roughly 29% to 39%.
For the same period, gross profit is projected to be between 63 million and 83 million yuan, while it was only about 380,000 yuan in the prior-year period, reflecting a staggering year-on-year growth of approximately 16,349% to 21,571%.
The substantial rise in revenue and sharp increase in gross profit for the first half of 2026 are primarily driven by higher revenue from the proton therapy business at the company's subsidiary, Guangzhou Taihe Oncology Hospital Co., Ltd. The cumulative number of patients treated has exceeded 1,000 cases, with a daily treatment volume reaching over 100 patients. Moving forward, the company will continue to optimize service procedures, enhance diagnostic and treatment efficiency, and strive to deliver high-quality medical services to more cancer patients.